mustang bio office

For each of our 895,879 listed executives, She attended Northeastern University and received her SPHR Certification in 2011.Lynn E. Bayless joined Mustang Bio as Head of Regulatory Affairs in 2020. Source: MarketScreener Mustang Bio: Mustang Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights (marketscreener.com) NEW YORK, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapies into potential cures for … Ms. Manning has more than 20 years of HR leadership experience leading the human resources function in biotechnology, clinical diagnostics and medical device environments. Niss has served as Chief Technology Officer since March 2018. Joining Mustang Bio offers the ability to be part of an engaged, driven team of scientists that are at the forefront of human science. Earlier in his career, Dr. Niss was Senior Technical Project Leader at Novartis’ cell therapy manufacturing facility in Morris Plains, New Jersey, where he directed the transfer and implementation of the CTL019 process from Penn to Novartis. He is a past president of the Society of Quality Assurance, an honorary life Fellow of the Research Quality Association, a lecturer in Purdue University’s Regulatory and Quality Compliance graduate program and he is the EPA industry representative to the OECD GLP discussion group.Dr. Earlier in his career, Dr. Litchman was a senior equity analyst at Ursus Capital and directed oncology / immunology clinical research at Hoffmann-La Roche Inc. Dr. Litchman received his M.D.

Receive alerts when executive After three unsuccessful trials, for your security, Prior to Amerigen, Mr. Achenbach served as Vice President of Finance for the Americas and Vice President of Global Financial Planning & Analysis at ConvaTec, a global medical products and technologies company, where he led finance and accounting operations in the U.S., Canada and South America. Mustang Bio (NASDAQ: MBIO) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Worcester, MA, U.S. Operating as a partner company of Fortress Biotech, Mustang Bio develops CAR-T immunotherapies and gene therapies for multiple diseases, including hematologic cancers, solid tumors, and X-linked severe combined immunodeficiency …

Add private notes. in microbiology from the University of Göttingen in Germany. While at Arvinas, Dr. Litchman oversaw the advancement of the company’s pipeline of protein-degradation therapeutics for the … Mustang Bio, Inc. is a clinical-stage biopharmaceutical company. 377 Plantation Street Worcester, MA 01605 781-652-4500 (phone) Dr. Niss joined Mustang in March 2017 as Vice President of Operations, where he initiated and oversees the establishment of Mustang’s cell therapy manufacturing facility. New York, NY 10014 Create an alert to follow the executive moves at Mustang Bio. Research efforts focused on developing products in several areas of cellular therapeutics, including placental mesenchymal stem cells, T cells, NK cells, CAR-T cells, CAR-NK cells and genetic modifications thereof. While at Arvinas, Dr. Litchman oversaw the advancement of the company’s pipeline of protein-degradation therapeutics for the treatment of cancers and other diseases toward Investigational New Drug applications, as well as the execution of multi-target discovery … Prior to Mustang, Mr. Achenbach served as Vice President & Corporate Controller at Amerigen Pharmaceuticals, where he oversaw finance and accounting functions as the company established itself as a commercial organization in the U.S. and China. Współpracuj bezpłatnie za pomocą wersji online programu Microsoft Word. from Princeton University. Prior to Mustang, Dr. Niss was Cell Therapy Asset Leader at Biogen, where he oversaw CMC-related activities for gene-edited hematopoietic stem cell and lentiviral gene therapy programs for sickle cell disease and hemophilia, respectively.

X-linked severe combined immunodeficiency (XSCID) is a rare genetic disorder that occurs in 1-2 per 100,000 births. He previously served as Director of Research Strategy and Innovation at Celgene Cellular Therapeutics, leading Intellectual Property, Research, Translational and Process Development for an autologous HPV antigen specific T cell product in early development. degree from Quinnipiac University in Laboratory Animal Technology/Pre-Veterinary Medicine and a minor in Microbiology.Greg Furrow joined Mustang Bio in January 2019 as head of Quality. The Company develops novel cancer immunotherapy products for the treatment of AML and brain cancer. Our world-class team of cell and gene therapy experts is developing next generation medicines in areas of high patient need Our unique model of Ms. Bayless has over 19 years of global regulatory experience in the biopharmaceutical industry focusing solely on biologics, including gene therapies, for orphan genetic diseases. Dr. Litchman joined Mustang from Arvinas, LLC, where he served as President and Chief Executive Officer. from the University of Maryland at College Park. Prior to Mustang, Dr. Edinger was Senior Director of Integrative Research and Strategy at Celularity, focused on scientific oversight of Intellectual Property, Research, Translational and Process Development in a matrixed environment, as well as driving scientific due diligence of external opportunities. MB-107 is an Ex vivo Lentiviral Therapy for X-linked Severe Combined Immunodeficiency. Udostępniaj je innym osobom i współpracuj nad nimi jednocześnie. Litchman joined Mustang from Arvinas, LLC, where he served as President and Chief Executive Officer. and M.S. Ms. Bayless received her M.S. Dr. Niss began his career in senior research positions in Pfizer’s Regenerative Medicine and Immunology groups. Ligand Pharmaceuticals has announced the acquisition of Pfenex ( Our partner company Mustang Bio, Inc. entered into exclusive, worldwide licensing agreements with City of Hope on patents covering five novel CAR T cell therapies in development for multiple forms of cancer: MB-101 (IL-13Rα2 CAR T), MB-102 (CD123 CAR T), MB-103 (HER2 CAR T), MB-104 (CS1 CAR T) and MB-105 (PSCA CAR T). Mustang Bio, Inc. operates as a clinical-stage biopharmaceutical company.

Mustang Bio has Mr. Achenbach holds an M.B.A. in finance from Roosevelt University in Chicago and a B.A.